Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7466
IPSCIO Record ID: 255948
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (â€œPeripheralâ€ in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.
IPSCIO Record ID: 289243
The Compound means the Milano variant of Apolipoprotein A-1.
Licensed Product means any pharmaceutical product including the Compound as its active ingredient the manufacture, use or sale of which would infringe one of the issued, valid unexpired claims or one of the pending claims contained in the Licensor Patent Rights in any country or involves use of the Licensor Know-How.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms. When severe, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney problems, depending on which arteries are affected.
IPSCIO Record ID: 29073
IPSCIO Record ID: 273380
— practice under the Patent Rights
— make, have made, use, lease, import, export and/or sell Licensed Products,
— sell, use and/or practice Licensed Services.
The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
— make, have made, use, lease and/or sell Licensed Products
— sell, use and/or practice Licensed Services.
The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.
The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.
IPSCIO Record ID: 25991
IPSCIO Record ID: 3640
IPSCIO Record ID: 291116
— an exclusive, worldwide license, with the right to grant sublicenses, under the Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field, and
— subject to any pre-existing rights of third Persons, a non-exclusive worldwide license, with the right to grant sublicenses, under the Know-How to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field.
Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. Atherosclerosis is the primary cause of coronary artery disease (CAD) and stroke, with multiple genetic and environmental contributions.
IPSCIO Record ID: 368507
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled â€œCompound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 279309
Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.
Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.
AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.
IPSCIO Record ID: 29203
IPSCIO Record ID: 230780
'Existing Patents' means the RSD930 and RSD1236 Patent Families (ApplicationNumbers US 09/328,540; PCT/CA99/00535; US 09/328,541; PCT/CA99/00534; PCT/CA00/01506; PCT/CA00/01507; PCT/CA00/01508; PCT/CA98/00842 and Thailand Patent Appl.# 045858; Taiwan Patent Appl.# 87114395; The Philippines Patent Appl. # 98/2246; and Malaysia Patent Appl. # Pl 9804017 and all patentm applications claiming priority therefrom or sharing at least one common priority therewith).
IPSCIO Record ID: 233152
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases.
IPSCIO Record ID: 3467
Researchers have demonstrated that a deficiency of BH4 can disrupt NO synthesis, resulting in a loss of normal endothelial NO production. This loss of endothelial NO production, commonly referred to as endothelial dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic vascular disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been shown to be a strong predictor of cardiovascular adverse events in a number of clinical studies.